Description
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases[1].—Cancer-programmed cell death–C89H126N24O18S—-[1]MILLER, Michael Matthew, et al. Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions. WO2014151634A1.–1629654-95-0–1852.17—-O=C(N([C@H](C(N([C@H](C(N[C@H](C(N[C@](CSCC(N[C@H](C(N([C@H](C(N[C@H](C(N1CCC[C@]1(C(N[C@]([H])(C(N[C@H](C(N(CC(N[C@H](C(N[C@H](C2=O)CO)=O)CC3=CNC4=CC=CC=C34)=O)C)=O)CC(C)C)=O)CC5=CN=CN5)=O)[H])=O)CC(N)=O)=O)C)C)=O)CC6=CC=CC=C6)=O)([H])C(NCC(N)=O)=O)=O)CCCNC(N)=N)=O)CCCC)C)=O)CCCC)C)[C@](N2)([H])CC7=CNC8=CC=CC=C78–Cancer–10 mM in DMSO–PD-1/PD-L1—-Immunology/Inflammation–Peptides
